|
Madopar
Contents:
Madopar '125' L-dopa 100 mg,
benserazide 25 mg.
Madopar '250' I-Dopa 200 mg,
benserazide 50 mg
Madopar HBS L-dopa 100 mg,
benserazide 25 mg
Indications:
Parkinson's disease & syndrome,
except drug-induced Parkinson syndrome.
Madopar HBS Patients with
fluctuations in response. For better control of nocturnal symptoms.
Dosage:
Initial: 1 cap Madopar '125'
three times daily,
increasing weekly until optimal therap dose.
HBS cap Individual
titration.
Nocturnal disability Up to
3 cap at bedtime.
Contraindications:
Severely decompensated endocrine,
renal, hepatic & cardiac disorders. Psychoses & severe psychoneuroses.
Patients < 25 year. Pregnancy. Combination with MAOIs ( except Selegiline ).
Special Precautions:
Glaucoma. History of myocardial
infarction (MI), coronary insufficiency, cardiac arrhythmia; peptic ulcer &
osteomalacia. Discontinue 1-2 days before surgery requiring general
anesthetic.
Adverse Reactions:
Anorexia, gastrointestinal (GI)
upsets ( mild ); cardiac arrhythmias & orthostatic hypotension. Abnormal
involuntary movements. Mild, transient leukopenia & thrombocytopenia ( rare
).
Drug interactions:
Potentiates effects of
sympathomimetics. Neuroleptics, vitamin B6.
Presentation/Packing
Cap 125 mg x 100's, 1000's.
Cap/Tab 250 mg x 100's, 1000's.
HBS cap 125 mg x 100's. |